Related references
Note: Only part of the references are listed.Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Antonio Omuro et al.
NEURO-ONCOLOGY (2018)
ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM)
David A. Reardon et al.
NEURO-ONCOLOGY (2017)
Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
RANDOMIZED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE 143
D. A. Reardona et al.
NEURO-ONCOLOGY (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial
Bogdana Suchorska et al.
NEURO-ONCOLOGY (2016)
Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Irinotecan-based regimens for recurrent glioblastoma multiform: a systematic review
Omar Abdel-Rahman et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
Eudocia Q. Lee et al.
NEURO-ONCOLOGY (2015)
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Kathryn M. Field et al.
NEURO-ONCOLOGY (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Irinotecan-based regimens for recurrent glioblastoma multiform: a systematic review
Omar Abdel-Rahman et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Bevacizumab and Glioblastoma: Scientific Review, Newly Reported Updates, and Ongoing Controversies
Kathryn M. Field et al.
CANCER (2015)
Addition of lomustine for bevacizumab-refractory recurrent glioblastoma
Michaela Tonder et al.
ACTA ONCOLOGICA (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Are we done with dose-intense temozolomide in recurrent glioblastoma?
Martin J. van den Bent et al.
NEURO-ONCOLOGY (2014)
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
Seunggu J. Han et al.
NEURO-ONCOLOGY (2014)
Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Evanthia Galanis et al.
CLINICAL CANCER RESEARCH (2013)
Standards of care for treatment of recurrent glioblastoma-are we there yet?
Michael Weller et al.
NEURO-ONCOLOGY (2013)
Salvage therapy with single agent bendamustine for recurrent glioblastoma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
Jennifer L. Clarke et al.
NEURO-ONCOLOGY (2011)
Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas
Shannon E. Fogh et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The role of salvage reirradiation for malignant gliomas that progress on bevacizumab
Roy G. Torcuator et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Salvage therapy with single agent bevacizumab for recurrent glioblastoma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Eudocia C. Quant et al.
NEURO-ONCOLOGY (2009)
Bevacizumab and chemotherapy for recurrent glioblastoma A single-institution experience
P. L. Nghiemphu et al.
NEUROLOGY (2009)
A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)
T. F. Cloughesy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Molecular targeted therapies and chemotherapy in malignant gliomas
Dieta Brandsma et al.
CURRENT OPINION IN ONCOLOGY (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
WB Pope et al.
NEUROLOGY (2006)
Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution
SE Combs et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
